⏳ Fetching live dividend data...
Home › Calculator › CMRX Dividend Calculator 2026
Chimerix, Inc. · NASDAQ
Price: $8.54 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CMRX → $2828392.22M in 10 years · $234,720,584,979.92/month
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CMRX position with:
Real after-tax yield depends on where you live and how you hold CMRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 19.91% | 17.11% | $1,991 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 18.74% | 15.94% | $1,874 / yr |
| 🇬🇧 UK ISA | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇬🇧 UK Taxable | 8.75% | 21.37% | 18.57% | $2,137 / yr |
| 🇨🇦 TFSA | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇨🇦 CA Taxable | 25% | 17.57% | 14.77% | $1,757 / yr |
| 🇦🇺 Super (pension) | 15% | 19.91% | 17.11% | $1,991 / yr |
| 🇦🇺 AU Taxable | 30% | 16.39% | 13.59% | $1,639 / yr |
| 🇩🇪 DE Taxable | 26.375% | 17.24% | 14.44% | $1,724 / yr |
| 🇫🇷 FR Taxable | 30% | 16.39% | 13.59% | $1,639 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CMRX pays quarterly — 4 times per year. Next ex-div: TBD.
How CMRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CMRX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-04-21 | 60,000 | $0.89 | $53.4K | ||
| D-Return | 2025-04-21 | 60,000 | $1.39 | $83.4K | ||
| D-Return | 2025-04-21 | 35,000 | $7.84 | $274.4K | ||
| D-Return | 2025-04-21 | 50,000 | $1.82 | $91.0K | ||
| D-Return | 2025-04-21 | 60,000 | $8.22 | $493.2K | ||
| D-Return | 2025-04-21 | 233,413 | $8.55 | $2.00M | ||
| D-Return | 2025-04-21 | 60,000 | $0.89 | $53.4K | ||
| D-Return | 2025-04-21 | 1,150,000 | $2.09 | $2.40M | ||
| D-Return | 2025-04-21 | 632,500 | $2.08 | $1.32M | ||
| D-Return | 2025-04-21 | 700,000 | $9.28 | $6.50M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CMRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →